Merck KGaA – Talk Bio

Immunome’s desmoid tumor drug varegacestat posts landmark Phase 3 results, setting up a potential challenge to Merck KGaA’s Ogsiveo

1 month ago talkbio0Tagged Fibromatosis, Aggressive, Frequency of Responses, gamma secretase inhibitor, Immunome, Infrequent, Merck KGaA, NDA, Neoplasms, Ogsiveo, Phase 3 RINGSIDE trial, Progression-Free Survival, varegacestat

Immunome; varegacestat; desmoid tumors; Phase 3 RINGSIDE trial; gamma secretase inhibitor; Merck KGaA; Ogsiveo; progression-free survival; objective response rate; rare tumors; oncology; NDA filing

Kai Beckmann Appointed as Successor to Merck KGaA CEO Belén Garijo, Effective May 2026

4 months ago talkbio0Tagged Belén Garijo, business career, CEO, Corporate, Electronic, Executive Board, governance, Health Care Sector, Kai Beckmann, Leadership Transition, Merck KGaA, strategic transformation, succession

Merck KGaA; Kai Beckmann; Belén Garijo; CEO Succession; Electronics Business; Executive Board; Leadership Transition; Healthcare sector; Corporate governance; Strategic transformation

Merck KGaA and Skyhawk Therapeutics Launch $2B RNA-Targeting Neurology Collaboration

5 months ago talkbio0Tagged Billion Collaboration, Drug Development, Merck KGaA, milestone payments, nervous system disorder, RNA-targeting, royalties, Skyhawk, SkySTAR platform

Merck KGaA; Skyhawk Therapeutics; RNA-targeting; SkySTAR platform; neurological disorders; $2 billion collaboration; drug development; milestone payments; royalties

Merck KGaA Forms $2 Billion Neurological Disease Pact with Skyhawk Therapeutics

5 months ago talkbio0Tagged Drug Discovery, Merck KGaA, milestone payments, Neurological diseases, RNA Splicing, Skyhawk, SkySTAR platform, strategic collaboration

Merck KGaA; Skyhawk Therapeutics; neurological diseases; RNA splicing; SkySTAR platform; drug discovery; strategic collaboration; milestone payments

Merck KGaA springs back into M&A game with $3.9B buyout of Pfizer spinout SpringWorks

9 months ago talkbio0Tagged disease treatments, Fibromatosis, Aggressive, Gomekli, KGaA, Merck KGaA, Neurofibromatosis 1, Ogsiveo, Pfizer, Pfizer/, pharmaceutical acquisition, SpringWorks

Pharmaceutical acquisition, rare disease treatments, Merck KGaA, SpringWorks Therapeutics, Ogsiveo, Gomekli, desmoid tumors, neurofibromatosis type 1 (NF1), Pfizer spinout